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Abstract
Background: Noninvasive ventilation is used worldwide in many settings. Its effectiveness has been proven for
common clinical conditions in critical care such as cardiogenic pulmonary edema and chronic obstructive pulmonary
disease exacerbations.
Since the first pioneering studies of noninvasive ventilation in critical care in the late 1980s, thousands of studies and
articles have been published on this topic. Interestingly, some aspects remain controversial (e.g. its use in de-novo
hypoxemic respiratory failure, role of sedation, self-induced lung injury). Moreover, the role of NIV has recently been
questioned and reconsidered in light of the recent reports of new techniques such as high-flow oxygen nasal therapy.
Methods: We conducted a survey among leading experts on NIV aiming to 1) identify a selection of 10 important
articles on NIV in the critical care setting 2) summarize the reasons for the selection of each study 3) offer insights on
the future for both clinical application and research on NIV.
Results: The experts selected articles over a span of 26 years, more clustered in the last 15 years. The most voted article
studied the role of NIV in acute exacerbation chronic pulmonary disease. Concerning the future of clinical applications for
and research on NIV, most of the experts forecast the development of innovative new interfaces more adaptable to
patients characteristics, the need for good well-designed large randomized controlled trials of NIV in acute “de novo”
hypoxemic respiratory failure (including its comparison with high-flow oxygen nasal therapy) and the development of
software-based NIV settings to enhance patient-ventilator synchrony.
Conclusions: The selection made by the experts suggests that some applications of NIV in critical care are supported by
solid data (e.g. COPD exacerbation) while others are still waiting for confirmation. Moreover, the identified insights for the
future would lead to improved clinical effectiveness, new comparisons and evaluation of its role in still “lack of full evidence”
clinical settings.
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Background
Noninvasive ventilation (NIV), as it is commonly known,
includes the application of negative pressure to the air-
ways by iron lung or body ventilators, the delivery of
noninvasive intermittent positive pressure ventilation
(NIPPV) or application of noninvasive continuous posi-
tive airway pressure (CPAP) via noninvasive interface.
NIV, used as NIPPV or CPAP, is nowadays, a medical
intervention used in daily practice worldwide in many
clinical settings. Since the first pioneering studies of
noninvasive ventilation in critical care in the late 1980s
[1–3] thousands of studies and manuscripts have been
published on this topic exploring different clinical appli-
cations, modalities, interfaces and comparisons with
other therapies [4, 5]. Its effectiveness has been proven
for common clinical conditions in critical care, such as
cardiogenic pulmonary edema (CPE) and exacerbation
of chronic obstructive pulmonary disease (COPD) [4–7],
as well as for ventilatory support for patients with venti-
latory pump failure and to prevent extubation failure
[8–10]. However, although extensively studied, some as-
pects remain controversial such as its role in hypoxemic
“de novo” respiratory failure, the best interface and ven-
tilatory modality to optimize patient-ventilator inter-
action and comfort and side effects (e.g. skin breakdown
and non-intentional air-leaks) [11–14]. Recently, its role
has been questioned and re-analyzed in light of a wide-
spread use of a new ventilator support mode (high flow
nasal therapy - HFNT), better drugs for sedation and
emerging patho-physiological concepts such as NIV-
induced lung damage due to high transpulmonary pres-
sure/driving pressure or generated tidal volume [15–20].
Thus, during the past decades, some NIV applications
have become established, others are being re-examined
and need further exploration in the near future. The
present survey among some of the worldwide leading
experts aims to: 1) select and review 10 important arti-
cles published on NIV in critical care setting 2) highlight
future directions for both research and clinical applica-
tions of this fundamental mode of ventilation that all
critical care physicians should be skilled in applying.
Methods
The selection of experts for this survey by the expert
group coordinator (Cesare Gregoretti) and the method-
ology group was based on: 1) The authors’ rank generated
by Web Of Sciencetm for the topic “noninvasive ventila-
tion” under the following categories: “Critical Care
Medicine”, “Anesthesiology”, “Emergency Medicine”; 2)
recognized scientific impact on this field. The experts re-
ceived an invitation letter including the aim of the project
and the instructions from the experts group coordinator
and the methodology group. The experts were asked to
select and rank 10 important articles published on NIV,
described as both NPPV and CPAP, in critically ill patients.
The studies could be randomized controlled trials (RCT),
nonrandomized, preclinical, clinical, systematic review or
any other type. The experts were also asked not to share
their opinion with other experts before finishing the task.
Along with the list, the experts gave reasons why they se-
lected each article. After sending their reports, experts re-
ceived another letter asking them to indicate at least one
important insight for research and/or clinical application
of NIV for the near future. After the tasks were com-
pleted, one investigator from the methodology group
assigned a random code to each expert. The investigators
who ranked the selections were blind to the experts’
names. The expert group coordinator was asked to pro-
vide his list of studies and insights for the future before
contacting other experts to avoid potential bias. Sixteen
experts were contacted and 12 accepted and completed
the task (Massimo Antonelli, Elie Azoulay, Giorgio Conti,
Annalisa Carlucci, Alexandre Demoule, Miguel Ferrer,
Cesare Gregoretti, Nicholas S. Hill, Samir Jaber, Paolo
Navalesi, Paolo Pelosi, Raffaele Scala). Three experts re-
fused and another expert sent his report but the selected
studies included not eligible articles and it was eventually
excluded. After collecting the forms, the methodology
group ranked the studies basing on the number of votes
for each study by the experts. In case of ex aequo, the
methodology group considered for ranking the number of
citations from SCOPUS database. The insights for the
future were also collected and reported.
Results
The forms completed by the experts are reported in the
Additional file 1. Table 1 summarizes the selection of 10
important articles by the experts. We provide the descrip-
tion of the selected studies ranked from tenth to first.
10. Nava S et al. Crit Care Med. 2005 Nov;33(11):2465–70
Nava et al. [21] in this multi-center RCT enrolled 97
consecutive patients, requiring >48 h of mechanical ven-
tilation and considered at risk of developing post-
extubation respiratory failure (i.e., patients who had hy-
percapnia, congestive heart failure, ineffective cough and
excessive tracheobronchial secretions, more than one
failure of a weaning trial, more than one comorbid con-
dition, and upper airway obstruction). After a successful
weaning trial, patients were extubated and randomized
to NIV delivered by a face mask for >8 h/day in the first
48 h (pressure support ventilation – PSV mode, pressure
13 ± 4.5 cmH2o and 5.3 ± 1.6 for PEEP) vs standard
medical treatment (SMT), namely additional oxygen
support. The primary outcome was the need for reintu-
bation according to standardized criteria. Secondary
outcomes were intensive care unit (ICU) and hospital
mortality, as well as time spent in the intensive care unit
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and in hospital. Compared with the SMT group, the NIV
group had a lower rate of reintubation (4/48 vs. 12/49 -
P = 0.027) and a lower ICU mortality. The need for rein-
tubation was associated with a higher risk of mortality.
Why this study? This is the first randomized controlled
study showing a role for NIV as a method for prevention of
post-extubation respiratory failure and reintubation in pa-
tients at high risk for reintubation. Prior to this study, some
not controlled studies demonstrated the efficacy of NIV as
after extubation in trauma patients [22] as in unweanable
spinal cord injury patients [23]. However, in other prior
RCT, NIV had not been found to reduce the need for rein-
tubation in unselected patients with respiratory failure after
extubation [24, 25] compared to SMT. Very interestingly,
in this study, arterial blood gases were normal at the time
of NIV initiation indicating that patients were not in re-
spiratory distress, differently from patients that were en-
rolled in the former studies on the use of NIV to prevent
post-extubation respiratory distress [24, 25]. These findings
were also in accordance with data reported by Ferrer et al.
published in the same year in a subgroup of COPD patients
after a post-hoc analysis [26]. So, we can conclude that NIV
should be applied early after extubation without waiting for
manifest acute respiratory failure (ARF).
9. Bersten AD et al. N Engl J Med. 1991 Dec 26; 325:1825–30
Bersten et al. [1] investigated in a randomized controlled
trial whether mask 10 cmH2O CPAP delivered via a face
mask had physiologic benefit and would reduce the need
for intubation and mechanical ventilation in 39 patients
with severe CPE and respiratory failure, compared to
standard oxygen alone. After 30 min, respiratory rate, pH,
arterial carbon dioxide tension and the ratio of Partial
Pressure of Arterial Oxygen to the Fraction of Inspired
Oxygen (PaO2/FiO2 ratio) had improved significantly
more in the CPAP group. Seven out of 20 patients who re-
ceived oxygen alone but none who received oxygen plus
CPAP required intubation and invasive mechanical venti-
lation (IMV) (P = 0.005). At 24 h, no difference was found
in respiratory indexes between groups.
Why this study? The first randomized trial showing
that noninvasive CPAP reduces intubation rate in
CPE. One of the earliest reports of positive airway
pressure for therapy of CPE was that by Poulton in
1936 [27]. Since then, no controlled study was carried
out on this topic. Bersten’s study was able to demon-
strate that the main benefits of applying a noninvasive
distending pressure, beyond avoiding intubation and
improving pulmonary function and oxygenation, are
the effects on the heart due to heart-lung interaction.
Applying CPAP may lead not only to a decrease in
pre-load but also, by decreasing negative pressure
swings and, increasing intrathoracic pressure, to a de-
crease in left-ventricular afterload (namely the trans-
mural ventricular pressure) [28, 29]. This study also
led to the publication of other several others studies
that tried to demonstrate whether CPAP has any
benefit in mortality [30, 31].
Table 1 Ten important articles published on NIV selected by the experts
Rank Study ID Title Votes from the Experts Citationsa
1 Brochard L et al. 1995 [34] Noninvasive ventilation for acute exacerbations of chronic obstructive
pulmonary disease
8 1361
2 Nava S et al. 1998 [39] Noninvasive mechanical ventilation in the weaning of patients with
respiratory failure due to chronic obstructive pulmonary disease
8 540
3 Hilbert G et al. 2001 [40] Noninvasive ventilation in immunosuppressed patients with pulmonary
infiltrates, fever, and acute respiratory failure
7 712
4 Antonelli M et al. 1998 [36] A comparison of noninvasive positive-pressure ventilation and conventional
mechanical ventilation in patients with acute respiratory failure
7 670
5 Jaber S et al. 2016 [35] Effect of noninvasive ventilation on tracheal reintubation among patients
with hypoxemic respiratory failure following abdominal surgery. A
randomized clinical trial
6 14
6 Plant PK et al. 2000 [33] Early use of non-invasive ventilation for acute exacerbations of chronic
obstructive pulmonary disease on general respiratory wards: a multicenter
randomised controlled trial
5 772
7 Brochard L et al. 1990 [3] Reversal of acute exacerbations of chronic obstructive lung disease by
inspiratory assistance with a face mask
5 428
8 Antonelli M et al. 2000 [32] Noninvasive ventilation for treatment of acute respiratory failure in
patients undergoing solid organ transplantation. A randomized trial
4 437
9 Bersten et al. 1991 [1] Treatment of severe cardiogenic pulmonary edema with continuous
positive airway pressure delivered by face mask.
3 431
10 Nava S et al. 2005 [21] Noninvasive ventilation to prevent respiratory failure after extubation
in high-risk patients
3 255
aThe number of citations for each article was retrieved from SCOPUS at the time of results analysis
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8. Antonelli M. et al. JAMA. 2000 Jan 12; 283(2):235–41
The study by Antonelli et al. [32] compared face mask
NIV (PSV mode to achieve an exhaled tidal volume of 8
to 10 mL/kg with PEEP up to 10 cmH2O) vs standard
treatment using supplemental oxygen administration to
avoid endotracheal intubation in 40 recipients of solid
organ transplantation with acute hypoxemic respiratory
failure. As previously shown in their former study in im-
munocompetent hypoxemic patients, within the first
hour of treatment significantly more patients in the NIV
group improved PaO2/FiO2 ratio. The use of NIV was
associated with a significant reduction in the rate of
endotracheal intubation (4/20 vs 14/20; P = 0.05), rate of
fatal complications, length of stay in the ICU by survi-
vors, and ICU mortality.
Why this study? The first randomized trial showing
potential benefits of NIV for immunocompromised pa-
tients with hypoxemic ARF to avoid the potential com-
plications of endotracheal intubation, opening the door
for this application of NIV. These results suggested that
transplantation programs should consider NIV in the
treatment of selected patients with ARF following solid
organ transplantation.
7. Brochard L et al. N Engl J Med. 1990 Nov
29;323(22):1523–30
Brochard et al. [3] tested the short-term (45-min) physio-
logic effects of face mask NIV delivered by means of a new
dedicated ventilator (PSV mode, pressure 15.5 ± 4,2 cm
H2O) and a facemask in 11 COPD patients with an acute
exacerbation. They found that pH, carbon dioxide, oxygen-
ation and respiratory rate all improved along with a re-
duction in the diaphragmatic electromyogram signal. In
addition, the authors evaluated the potential therapeutic
efficacy of NIV in 13 COPD (including 3 of the 11 in
physiologic study) who were treated with NIV for several
days. Only 1 of these patients needed IMV compared to 11
of the 13 historical controls (P < 0.01).
Why this study? At the time the study was conducted
patients with an acute exacerbations of COPD often re-
quired IMV. This seminal study is a “corner stone” in
the field of NIV overall for its physiologic findings and
for “opening the door” to NIV use for acute exacerbation
of COPD patients in the ICU. It demonstrated for the
first time the feasibility of using intermittent positive air-
way pressure delivered by a facemask to obviate the need
for IMV in COPD patients with hypercapnic respiratory
failure due to an acute exacerbation, the preferred way
of managing such patients.
6. Plant PK et al. Lancet. 2000 Jun 3;355(9216):1931–5
Plant et al. [33] aimed in a prospective multicentre RCT
at finding whether a nasal or face mask NIV use, early
after the admission on a general respiratory ward, was
effective at reducing the need for IMV and mortality. As
done by Brochard et al. in ICU [34] they compared in
236 patients the efficacy of 1) facemask NIV (using bi-
level positive airway pressure – PAP – mode) plus SMT
vs 2) SMT alone in COPD patients with mild to moder-
ate acidosis. Bi-level positive airway pressure was set was
initially set at 10 cm H2O of inspiratory pressure and
then increased in increments of 5 cmH2O to 20 cm H2O
or the maximum tolerated over 1 h. PEEP was set at
4 cm H2O pressure. The major finding of this study was
that the early use of NIV for mildly and moderately acid-
otic patients leads to more rapid improvement of
physiological variables, a reduction in the need for inva-
sive mechanical ventilation (with objective criteria), and
a reduction in in-hospital mortality.
Why this study? At the very beginning of the present
century, it was already clear that NIV in an ICU could
avert the need for intubation and the mortality associ-
ated with severe episodes of COPD exacerbation [3, 34].
However, no study had yet addressed the timing of the
use of NIV in a general respiratory ward. This was the
first RCT demonstrating the feasibility of using NIV in
acute exacerbations of COPD patients outside the ICU.
The study supported the idea that early application of
NIV in COPD patients with milder ARF improved pa-
tients’ outcomes. It furthermore demonstrated that pa-
tients with a COPD exacerbation and less severe
respiratory acidosis (≥7.30) could be safely managed on
a respiratory ward, whilst those with more severe acid-
osis would need settings with more staff and equipment.
5. Jaber S et al. JAMA. 2016 Apr 5;315(13):1345–53
In this multicenter, randomized, parallel-group clinical
trial Jaber et al. [35] studied 293 patients admitted to 20
ICU who had undergone abdominal surgery (laparoscopic
or nonlaparoscopic elective or nonelective) and developed
hypoxemic respiratory failure (PaO2 < 60 mmHg or
SpO2 < =90% in association with other signs of respiratory
failure). Patients were randomly assigned to receive stand-
ard oxygen therapy or face mask NIV (PSV mode, pres-
sure 6.7 ± 3 cm H2O and PEEP 5.4 ± 1 cmH2O). NIV
reduced the risk of tracheal reintubation within 7 days,
the primary outcome variable (49/148 vs 66/145 in con-
trols; CI −23.5% to −1.3%; P = 0.03). In addition, NIV was
associated with significantly more invasive-free days at day
30 and a lower occurrence of health care-associated infec-
tions compared with standard oxygen therapy. There were
no significant differences in gas exchange or mortality at
90 days.
Why this study? The first large positive RCT on the
use of NIV for ARF in the post-abdominal surgery that
established the role of NIV in reducing the need for in-
vasive mechanical ventilation (IMV). The main finding
of the present study was that it was targeted, beyond to
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find differences in arterial blood gases (secondary
outcome), to find differences in tracheal reintubation
(primary outcome) for any cause within 7 days of
randomization. However mortality did not change at
90 day probably meaning that other factors than invasive
mechanical ventilation would interfere with mortality rate.
4. Antonelli M et al. New Eng J Med. 1998 Aug
13;339(7):429–35
Antonelli et al. [36] conducted a prospective, random-
ized trial of face mask NIV (PSV mode with pressure
level set above PEEP) vs IMV in 64 patients with hypox-
emic ARF requiring mechanical ventilation. PSV was in-
creased to achieve an exhaled tidal volume of 8 to 10 ml
per kilogram. PEEP was increased in step of 2 to 3 cm
H2O up to 10 cm H2O.
They showed that NIV was as effective as IMV in im-
proving the PaO2/FiO2 ratio within the first hour (20 of
32 patients – 62% - in the NIV group and 15 of 32–47%
- in the IMV group; P = 0.21). Ten patients in the NIV
group (31%) subsequently required endotracheal intub-
ation. More patients in the IMV group had serious com-
plications (including sinusitis, pneumonia, myocardial
infarction, cardiogenic shock, sepsis) and longer periods
of ventilation and stays in the ICU.
Why this study? Although the role of NIV in hypox-
emic patients is nowadays still debated [37] this was the
first RCT to suggest a possible role for NIV in patients
with hypoxemic ARF. This was also the first and only
study comparing intermittent positive NIV (and not only
CPAP) with IMV. This study is important because it first
proved that NIV could improve arterial blood gases as
IMV on the short-term basis.
3. Hilbert G et al. N Engl J Med. 2001; Feb 15;344(7):481–7
Hilbert et al. [15] studied 52 immunosuppressed patients
(mainly hematologic malignancies) with pneumonitis,
fever and ARF comparing intermittent 45 min trial of
face mask NIV (PSV mode, pressure 15 ± 2 cm H2O
and PEEP 6 ± 1 cm H2O) plus SMT to SMT alone in-
cluding supplemental oxygen. The primary outcome was
intubation and mechanical ventilation at any time during
the study. Significantly fewer patients in the NIV group
(12/26–46%) than in the standard-treatment group (20/
26–77%) required endotracheal intubation (P = 0.03),
had serious complications or died in the ICU. Hospital
mortality was reduced from 80% in controls to 50% in
the NIV group, with 100% mortality among the controls
who required intubation.
Why this study? This was the first randomized con-
trolled trial showing benefits of using NIV in immuno-
compromised patients with pulmonary infiltrates, at an
early stage of ARF, to prevent complication of IMV. The
authors gave the important message that in selected
immunosuppressed patients, early NIV initiation can be
associated with significant reductions in the use of IMV
and its related complications thus improving the likeli-
hood of survival. Very interestingly after many years,
avoiding intubation, independently from the NIV use, is
still a desirable goal in the management of respiratory
failure in immunosuppressed patients to avoid no-
socomial infections and bleeding related to hematologic
defects [38].
2. Nava et al. Ann Inter Med. 1998 May 1;128(9):721–8
In this multicenter, randomized trial Nava et al. [39] com-
pared extubation within 48 h of IMV and application of
noninvasive PSV mode (pressure 19.0 ± 2.0 cm H2O)
through a facial mask compared to invasive PSV in 50
COPD patients admitted in 3 respiratory ICUs. At 60 days,
22 of 25 patients (88%) in the NIV group were successfully
weaned compared to 17 of 25 (68%) (P < 0.01) who con-
tinued with IMV. Early extubation and application of NIV
also significantly reduced also the duration of mechanical
ventilation, ICU length of stay, and the occurrence of
nosocomial pneumonia and was associated with a signifi-
cantly better 60-day survival rate than IMV.
Why this study? At the time of the study, as with the
two seminal studies by Brochard et al., IMV was consid-
ered the preferred mode of ventilation for COPD
patients with ARF [3, 34]. The rate of weaning failure
was high leading to prolong mechanical ventilation, pre-
disposing to associated complications. This was the first
study showing the usefulness of NIV as a tool for early
extubation in selected intubated COPD patients with
difficulty weaning. This was also the first study demon-
strating that NIV can serve as a technique to avoid re-
intubation in this subgroup of patients.
1. Brochard L et al. N Engl J Med. 1995 Sep
28;333(13):817–22
Brochard et al. [34] conducted a multicenter, prospect-
ive, randomized trial in 85 COPD patients admitted to 5
ICUs with acute exacerbations to compare the efficacy
of face mask NIV (PSV mode set initially at 20 cm H2O)
plus SMT to SMT alone. Only 11 out of 43 (26%) in the
NIV group required intubation, as compared to 31 of 42
(74%) in the standard-treatment group (P < 0.001). NIV
also significantly reduced the hospital stay, and the in-
hospital mortality rate.
Why this study? After their study carried out five years
before [3] which found that NIV was effective in down-
loading respiratory muscles and improving arterial blood
gases in COPD patients with an acute exacerbations. The
authors demonstrated that NIV was able to reduce the
proportion of COPD patients with ARF needing IMV and
to improve their outcome. It also established for the first
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time the indication for NIV in COPD exacerbations with
respiratory acidosis.
Discussion
To the best of our knowledge, this is the first report of
experts’ selection and opinions on 10 important articles
on NIV in critical care. This study also provides future
insights on NIV.
The experts selected articles in a span of twenty-six
years with the articles more clustered in the last fifteen
years. The most voted article was published in 1995 [34].
Nevertheless, one selected article was published in 2016
meaning that NIV is still stimulating high quality re-
search after many years of research of investigation and
clinical application [35]. Five selected articles focused on
acute exacerbations of COPD inside and outside the
ICU, two on NIV use in hypoxemic respiratory failure,
two on immunosuppressed and transplant patients and
one to prevent respiratory failure after extubation in
high-risk patients. This result was expected taking into
account the solid evidence for NIV to treat acute exacer-
bations of COPD. Since the time of the Brochard’s study
[34], ranked as 1st, NIV has become the first line ther-
apy when ventilator assistance is deemed indicated in
acute exacerbations of COPD.
The study of Hilbert et al. on immunosuppressed pa-
tients was ranked as 3rd [40]. Recently, Lemiale et al.
found that early NIV compared with standard oxygen
therapy alone did not reduce intubation rate or 28-day
mortality in immunosuppressed patients with hypoxemic
ARF [38]. However, the study has been found to have
limitations, including the use of HFNT in nearly 40% of
patients in both treatment and control groups [37, 41,
42]. A more recently published subgroup analysis of the
outcomes of immunocompromised patients with ARF in
the FLORALI (HFNT vs standard oxygen vs NIV) study
found higher intubation and mortality rates associated
with NIV than HFNT use, further raising concerns
about the efficacy of NIV in this subgroup of patients
[43]. Indeed, in hypoxemic patients, keep using NIV and
thus delaying invasive ventilation may expose the pa-
tients to the effects on an increased transpulmonary
pressure namely the sum of the pressure applied to the
airway by the ventilator and the pleural pressure gener-
ated by the patient’s spontaneous effort [41]. The pres-
sure generated by the respiratory muscles added to the
level of patient-synchronized pressure support level [44]
may generate high tidal volumes higher than those con-
sidered safe for lung. In addition, during NIV, the level
of positive end expiratory pressure (PEEP) may be not
sufficient to recruit consolidated dependent lung areas
[45]. Eventually, it may cause a “self induced ventilation
lung injury” [46]. However, recently, Demoule et al.
found an increase in NIV use and success rate, an
overall decrease in mortality, and a decrease of the ad-
verse impact of NIV failure in hypoxemic patients com-
pared to data collected in France 10 years before [47,
48]. This may suggest a link between better patient se-
lection and greater proficiency of staff in administering
NIV and patients’ outcome.
Interestingly only one study investigated the use of
CPAP in CPE [1]. This is a surprising finding because of
the widespread clinical use of CPAP (or PS/PEEP) in
CPE [6]. Probably the use of CPAP is so established in
many countries that our experts rated only the first pio-
neering study as important. However, there are still con-
trasting results between the use of CPAP or NPPV in
CPE regarding avoidance of intubation and mortality
[30]. The issue is not just whether noninvasive CPAP
leads to a decreased mortality, although there is evidence
from meta-analysis that it does [6], but also whether it
can decrease length of stay, reduce hospital costs and
prevent hospital readmissions in heart failure [49].
Absent were some pioneering articles as the one pub-
lished by Meduri in 1989 [2] and articles related to the
use of pre-oxygenation before endotracheal intubation
and those referring to patient-ventilator dyssynchrony,
use of interfaces as mouth piece [50], or use of NIV in
the palliative care setting [51, 52]. Articles on these
topics were suggested by some reviewers (see Additional
file 1), but were not voted frequently enough by the ex-
perts to be ranked in the 10 selected articles [53–55].
Surprisingly there are not studies related to airway hu-
midification during NIV. Humidification and warming of
the inspired gas may be needed to prevent the adverse
effects of cool, dry gases on the airway epithelium [56].
Data on the level of humidity delivered with different
humidification strategies during NIV, demonstrated that
active humidifiers and heat and moisture exchangers
provide gas with the highest water content compared to
no humidification [57].
The experts’ insights and predictions for the future of
clinical applications and research for NIV are reported
in Table 2. Most of the experts listed one or more of the
following points:
1) The need is great for development of innovative new
interfaces that adapt better to patient facial
characteristics, are more confortable and leak less.
The choice of the interface has long been known
to be crucial for the success of NIV in both the
acute and chronic settings. Type (oral, nasal, nasal
pillows, oro-nasal or hybrid mask), size, design,
material and headgear may affect the patient’s
comfort in many ways, such as discomfort, air-
leaks, claustrophobia, skin erythema, eye irritation,
skin breakdown and facial deformity in children
[58, 59]. However, although the availability of
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interfaces and the likelihood of meeting patient
need is much better today than in the past, for
patients needing at least several hours of NIV per
day, both in acute and chronic settings, the ideal
interface does not yet exist. So the question
“facing” the future is: what direction to take to
develop better interfaces for NIV?
2) What is the best noninvasive approach to treat
hypoxemic respiratory failure? Most of the authors
stressed the need for good well-designed, large RCT
of NIV in acute “de novo” hypoxemic ARF not
restricted to immunosuppressed patients especially
to address the role of NIV compared to IMV. In
other words, we got the feedback that there is a need
for trials to replicate the Frat et al. study [42]. These
authors found that the use of HFNT reduced ICU
and 90-day mortality as compared to standard
oxygen and NIV. The authors speculated that the
greater mortality with NIV might have been related
to the use of tidal volumes greater than 9 ml/kg,
predisposing to ventilator-induced lung injury.
However, NIV was used intermittently and not
continuously. Moreover, the level of noninvasive
pressure-support was only of 8 ± 3 cmH2O of water,
PEEP only of 5 ± 1 cmH2O. In addition it can be
hypothesized that the use of other interfaces as
helmet [60]. could have increased patient tolerability
and time on NIV.
3) Last but not least improving patient-ventilator
synchrony still remains an important issue [61].
Developing software-based NIV setting and/or new
“fully noninvasive” triggering systems able to
enhance patient patient-ventilator synchrony, correct
auto-cycling and avoid wasted triggering efforts in
presence of moderate or high air leaks [62].
This survey has limitations. Firstly, although the panel
included a remarkable number of leading experts, a few
did not complete the task after the invitation and others
were not invited. It may be possible that, with a higher
number of experts we would have had different results.
However, we based the selection of experts not only on
the rank from a public database and on scientific merit
but also on professional background (e.g. intensivists
Table 2 Future insights for the future of NIV reported by the experts
Expert’s code What are the insights for the future on NIV?
1 • “A good, well-designed, large randomized controlled trial of NIV vs. oxygen in acute de novo hypoxemic respiratory failure,
not specifically designed for immunocompromised patients”
• “The perfect interface”
• “Reliable early predictors of NIV failure”
2 • “Randomized controlled trial of HFNT + NIV vs continuous NIV vs HFNT in hypoxemic respiratory failure”
3 • “Comparison of HFNT vs NIV in acute hypoxemic respiratory failure, performed according to the usual practice (in the Frat’s paper
NIV was not really the clinical practice)”
4 • “The most important insight for the future is the development of HFNT in conjunction and not as an absolute replacement for NIV”
5 • “New inclusion criteria: better definition of patients clinical characteristics to be assisted by NIPPV/CPAP, timing of treatment
initiation and interruption”
• “New devices: new masks and interfaces more adaptable to patients”
• “New comparisons: NIV vs invasive ventilation is hypoxemic respiratory failure and severe COPD. Most of studies have compared
NIV with oxygen delivered by a Venturi systems!”
• “New modalities of monitoring: development of accurate and precise non invasive CO2 monitoring as well as inspiratory efforts
during NIV. Development of accurate and precise non invasive monitoring of lung morphological changes during NIV (for example
quantitative sonography)”
6 • “Early treatment of acute hypercapnic respiratory failure and hypoxemic respiratory failure, even outside the ICU.
• “Mild to moderate hypoxemia in patients who do not improve with HFNT”
• “Patients with acute respiratory failure and do-not intubate orders”
7 • “We will see some reduction in use of NIV as HFNT makes inroads into the use of NIV for hypoxemic respiratory failure and perhaps
somewhat for hypercapnic respiratory failure (at least in milder cases)”
• “Extracorporeal CO2 removal will be used instead of NIV in hypercapnic patients at high risk of NIV failure”
8 “The most important insight for the future of NIV will be the development of innovative characteristics of interfaces material, able to
improve patient’s comfort and biocompatibility”
10 • “A software-based setting of NIV adjusted according to flow/pressure curves and SpO2 to achieve the best PS/PEEP levels and FiO2”
11 • “The most important insight for the future is to succeed in developing a new trigger system able to capture and correct autocycling
and wasted effort in a fully noninvasive way, despite the presence of moderate or high air leaks”
12 • “When we evaluate outcomes, we should consider them not only as a result of a binary option of intervention (NIV or no-NIV) but rather
as a function of the time spent under each of available interventions (e.g. O2, HFNT, CPAP, IMV)
• “We also need to stratify patients according to the underlying pulmonary disease/condition”
• “To replicate Antonelli et al. [36] study in other immunocompromized patients population”
HFNT high-flow nasal therapy; Expert 9 did not provide the insights
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working in general ICU, pulmonologists working in re-
spiratory ICU) in order to include different points of view
and to have balanced results. Moreover, 11 out of 12 au-
thors were Europeans. Although it may be argued that a
more balanced contribution from experts with cultural di-
versity would have increased the relevance of the study,
no other author from other countries met our inclusion
criteria and this may reflect a geographic unbalance in sci-
entific production. Other authors did not give their avail-
ability after been asked to participated to the study.
Second, the request to the experts was to provide only 10
important studies that globally changed their practice and
improve knowledge on the topic globally. Many important
studies may have been excluded since ten is a relatively
low number considering the very high volume of studies
published on this field. Other studies beside on those
listed in Table 1 may be retrieved in the Additional file
reporting the original lists from the experts.
It may be argued that experts might have been prone to
recall and indicate studies in which they had been involved
or they were not aware of other articles on the subjects,
leading to a bias and potential competing interest. Third,
experts’ selection did not include any study with negative
results or harmful effects of NIV compared to other forms
of ventilatory management [42, 63]. In all areas of know-
ledge, and mainly in medicine, learning what not to do is
so important, or even more, as than the recommendations
of what should be done. Although we discussed patho-
physiological and clinical insights from these findings, ex-
perts’ selection did not include studies with these results.
Conclusion
We performed an eminence-based selection of 10 import-
ant articles published to date on NIV in critical care setting.
The articles investigated the use of NIV in COPD exacer-
bations, in immunocompromized patients, in hypoxemic
ARF, in the postoperative management of major abdominal
surgical patients and for the treatment of respiratory failure
in CPE. Experts identified as insights for future research
the development of better interfaces, the use of NIV in the
setting of “de-novo” respiratory failure and its comparison
with HFNC in a large, well-designed, randomized study
and the development of more efficient, software-based,
NIV settings to enhance patient-ventilator synchrony.
While some applications of NIV are an important ac-
quisition, after many years from its institution, other are
still to be investigated. In conclusion, we are still playing
an “ongoing game”.
Additional file
Additional file 1: Ten important articles on NIV from each expert.
Standard forms reporting the articles and the reasons for selection from
each expert. The forms are anonymously reported. (PDF 524 kb)
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